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ABSTRACT
Mitral valve regurgitation (MR) is an important clinical issue as MR represents >30% of native valve 
diseases. Patients with symptomatic MR have a poor prognosis, with a 5% annual mortality rate in the 
absence of surgery. Optimal medical management can improve symptoms of heart failure but does not affect 
survival. Therefore, surgery is recommended by the current guidelines for patients with symptomatic severe 
MR or asymptomatic severe MR with evidence of left ventricular (LV) dysfunction or dilation. Despite the 
guidelines, a recent European survey established that one-half of the patients are not referred for surgery, 
mainly because of advanced age and the presence of comorbidity. Mitral valve (MV) repair is the preferred 
surgical strategy whenever feasible and is associated with lower morbidity and mortality and better 
preservation of LV function, compared with MV replacement. Reported in-hospital mortality rates range 
from 1% to 2% in low-risk patients, increasing up to 25% in high-risk or elderly patients. Therefore, new 
percutaneous techniques are developed to avoid surgery in high-risk patients (1).
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The transcatheter edge-to-edge MV repair us-
ing the MitraClip system creates a double MV orifice 
by means of a clip in the mid portion of the 2 leaflets 
and mimics the surgical procedure introduced by Al-
fieri et al. (1). Edge-to-edge surgical repair of the mi-
tral valve with annuloplasty (or without annuloplas-
ty in selected patients) has been shown to afford fa-
vourable outcomes in patients with degenerative or 
functional MR (FMR) (1).
Functional mitral regurgitation is a direct con-
sequence of underlying left ventricular dysfunction 
and annular dilation which secondarily impairs the 
coaptation of otherwise structurally normal leaflets. 
Surgical correction of FMR has been shown to im-
prove functional class and left ventricular remodel-
ling, but a survival benefit has yet to be shown (1). 
Additionally, even with current surgical annulo-
plasty techniques, up to 35% of treated patients have 
moderate or greater MR reoccur within 1 year of sur-
gery (1).
The anatomical criteria are mainly obtained by 
transesophageal echocardiography. All these criteria 
are preliminary and the exclusion criteria could rep-
resent a relative contraindication for the procedure 
(2). The main criterion is jet location. The current-
ly designed MitraClip™ can only be used to treat MR 
originating from the central portion of the valve (A2-
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P2 segments). Baseline valve area is also an impor-
tant factor associated to post-procedural trans-mi-
tral gradient. MitraClip™ should not be implanted in 
case of a valve area below 4 cm2. For the same reason, 
the procedure is not indicated in case of limited leaf-
let pliability (as in rheumatic disease). Also, any leaf-
let organic disease (perforations, calcifications, ero-
sions, etc.) should be considered a relative contrain-
dication to the procedure.
As for other transcatheter valve procedures, 
MitraClip™ interventions are ideally performed by a 
multidisciplinary team composed of surgeons, inter-
ventional and non-interventional cardiologists and 
anesthesiologists.
The surgical technique of Alfieri involves the 
use of suture to convert a regurgitant mitral orifice 
into a competent double orifice valve with decreased 
or eliminated regurgitation. The MitraClip device, 
which was designed to mimic an edge-to-edge repair, 
consists of a percutaneously delivered MRI-compati-
ble cobalt chromium implant with two arms and two 
grippers which are used to grasp the opposing free 
edges of the anterior and posterior leaflet in order to 
improve leaflet coaptation and generate a double-or-
ifice valve. Each arm is 4 mm wide and 8 mm long, 
and the device is covered in a polyester fabric to pro-
mote tissue in-growth. Complete encapsulation of 
the device occurs by 12 weeks (2,3).
The procedure is performed in the catheteriza-
tion laboratory under general anaesthesia for patient 
comfort (due to use of TEE during the procedure), 
but more importantly to eliminate patient movement 
and to perform controlled breath-holding during the 
MitraClip grasping step, thereby allowing accurate 
placement and controlled leaflet insertion.
MitraClip therapy is highly compatible with 
other minimally invasive procedures that are often 
applied to patients with MR. For example, access to 
the left atrium is not restricted for atrial fibrillation 
ablation procedures, and access to the coronary sinus 
is preserved for biventricular lead ICD placement or 
for future coronary sinus mitral annuloplasty devic-
es. Biventricular pacing and cardiac resynchroniza-
tion therapy is an important treatment for patients 
with ischaemic cardiomyopathy and can reduce 
FMR acutely and chronically in selected patients. 
Greater than one-half of responders to CRT have sus-
tained reductions in MR by at least one grade for 6 
months or longer (1).
The EVEREST I, EVEREST II and REALISM 
clinical studies (2,3) have evaluated the MitraClip 
device in patients diagnosed with mitral regurgita-
tion. The clinical data from these trials have demon-
strated that the MitraClip device and the procedure 
is safe. The MitraClip device has also been shown to 
effectively reduce MR, improve left ventricular func-
tion, and improve clinical outcomes, as evidenced by 
improvements in NYHA Functional Class and im-
provements in Quality of Life (QoL) in patients with 
significant MR.
The EVEREST I Feasibility Study evaluated the 
safety of the MitraClip device (2,3). The EVEREST 
II Randomized Clinical Trial compared the safety 
and effectiveness of the MitraClip device to conven-
tional open-heart surgical mitral valve repair (3). The 
EVEREST II High Risk Registry evaluated the safe-
ty and effectiveness of the MitraClip device in high 
risk surgical candidates (3). The EVEREST II REAL-
ISM Continued Access Registry evaluate the safety 
and effectiveness of the MitraClip device in high risk 
and non-high risk patients (3). Follow-up on patients 
enrolled in the EVEREST I and EVEREST II clini-
cal trials, including REALISM, continued for 5 years. 
The purpose of the Cardiovascular Outcomes 
Assessment of the MitraClip Percutaneous Thera-
py for Heart Failure Patients with Functional Mitral 
Regurgitation(COAPT) Trial is to confirm the safe-
ty and effectiveness of the MitraClip System for the 
treatment of moderate-to-severe or severe function-
al mitral regurgitation (FMR) in Symptomatic Heart 
Failure Subjects (5).
Data from ACCESS-EU (5,6) demonstrated 
that in real-world, post-approval experience in Eu-
rope, patients undergoing the MitraClip therapy 
have a predominantly high surgical risk, elderly pa-
tients who are mainly affected by functional MR, a 
type of MR in which a damaged heart impairs the 
performance of a normal mitral valve. ACCESS-EU 
showed that in this patient population, the MitraClip 
procedure demonstrated low rates of hospital mor-
tality and adverse events and provided significant 
improvements in day-to-day quality of life at one 
year following treatment.
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The first clinical trials with the MitraClip 
showed very promising results regarding the feasibil-
ity and safety of the device, and functional improve-
ment of the patient (2,3).
As a result of MR reduction, diminished plas-
ma NT-proBNP levels, accompanied with signifi-
cant improvements in QoL and functional capaci-
ty, which may be the primary goal in this challeng-
ing high-risk population. The improvement in ob-
jective parameters shows that the observed clinical 
effect can be attributed to improvements beyond a 
placebo effect. NYHA functional class improved in 
89% of this population, which is in line with previous 
reports. The EVEREST II trial showed similar im-
provements in NYHA functional class and QoL in 
both the clip and surgery subgroups at 12 months (3).
Percutaneous MV repair seems to be associated 
with positive reverse LV remodeling a significant in-
crease in LVEF, decrease in LVEDD, and obvious im-
provements in LV volumes (5). The question remains 
whether this will affect long-term prognosis, as pre-
vious reports showed no evidence that surgery for 
functional MR prolongslife, LV reverse remodeling.
CONCLUSION
Percutaneous approaches become a valuable 
treatment option for an important number of pa-
tients with severe (especially functional) MR who 
cannot undergo surgery. In the future, the field of 
percutaneous transcatheter MV repair will undoubt-
edly evolve exponentially, because functional MR is 
primarily a disease of the LV, a combination of the 
edge-to-edge repair with other percutaneous tech-
niques addressing the annulus and the LV itself will 
be necessary to provide durable correction and satis-
factory long-term outcomes.
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